Par Drugs And Chemicals Intrinsic Value
Valuation
Blended fair value using DCF and peer comparison methods.
Par Drugs And Chemicals Intrinsic Value Analysis
The latest available EOD closing price for Par Drugs And Chemicals (PAR) is ₹165 per share. Understock's estimated intrinsic value is ₹1,445 per share. This estimate is 775.9% above that price; the page's comparison band labels the shares undervalued.
The stored DCF estimate is ₹622, and the peer-based estimate is ₹2,268. The displayed value combines them using the stored DCF weight of 50% and peer weight of 50%. Peer comparison uses 4 matched sector companies and contributing P/E, P/B, EV/EBITDA multiples.
For context, available company data reports ROCE of 11.6% and P/E of 15.4×. These metrics describe the business and are not separate intrinsic-value estimates.
How Understock Calculates Intrinsic Value
Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For Par Drugs And Chemicals, the displayed estimate uses both stored values and their respective weights. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.
Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See Par Drugs And Chemicals peer valuation · What intrinsic value means
The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
Par Drugs And Chemicals Peer Comparison
How this company stacks up against sector peers on valuation and quality metrics.
Pharmaceuticals · 4 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Par Drugs And Chemicals PAR · you | ₹74 Cr | 15.4× | 1.8× | 0.3× | 11.7% | 12.6% | 2.7% |
| Sector median | — | 29.2× | 3.5× | 9.5× | 14.5% | 6.9% | 12.8% |
| Medico Remedies Limited MEDICO | ₹352 Cr | 26.8× | 4.7× | 21.6× | 17.4% | 6.4% | 13.7% |
| Medicamen Biotech Limited MEDICAMEQ | ₹291 Cr | 31.6× | 1.1× | 15.4× | 3.5% | 4.9% | 12.0% |
| Tembo Global Industries Limited TEMBO | ₹65 Cr | 11.0× | 2.3× | 0.3× | 20.2% | 8.4% | 63.4% |
| Bafna Pharmaceuticals Limited BAFNAPH | ₹42 Cr | 41.5× | 4.8× | 3.5× | 11.5% | 7.4% | 9.3% |
Par trades at a discount to sector peers on P/E (15.4× vs median 29.2×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.
How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.